(Hypertension. 2001;37:1179.)
© 2001 American Heart Association, Inc.
Scientific Contribution |
C-Type Natriuretic Peptide–Induced Vasodilation Is Dependent On Hyperpolarization in Human Forearm Resistance Vessels
From the Department of Vascular Medicine (M.L.H.H., T.J.R.), University Hospital Utrecht; Kendle (P.J.M., M.L.H.H.), Clinical Pharmacology Unit, Utrecht; the Department of Internal Medicine and Clinical Pharmacology (P.S.), University Hospital Nijmegen, the Netherlands; and the Mayo Clinic and Foundation (J.C.B.), Rochester, Minn.
Correspondence to Prof Dr Ton J. Rabelink, Department of Vascular Medicine, University Hospital Utrecht, Room F02.126, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. E-mail T.Rabelink{at}digd.azu.nl
Abstract—Animal studies have demonstrated that CNP causes endothelium-independent vasodilation, which is limited by neutral endopeptidase (NEP) activity. However, the vasodilating mechanism of CNP in humans is still unknown. Therefore, we investigated the vasodilator actions of CNP in human forearm resistance vessels before and after inhibition of nitric oxide (NO) and then prostacyclin production and after inhibition of Ca2+-dependent potassium channel activation and NEP activity. Three separate studies were performed. In each study, forearm blood flow was recorded by venous occlusion plethysmography in 8 healthy nonsmoking subjects. Brachial artery infusion of CNP (70, 140, 280, and 560 ng per 100 mL forearm volume per minute) caused significant forearm vasodilation in all studies (forearm blood flow from 3.94 to 8.50 mL per 100 mL forearm volume per minute). Inhibition of the endogenous generation of NO by L-NG-monomethyl arginine (by use of the NO-clamp technique) did not block the maximal vasodilating effects of CNP (forearm blood flow from 3.69 to 6.93). In addition, when the cyclooxygenase system was inhibited by 600 mg of acetylsalicylic acid (aspirin) administered orally 30 minutes before start of measurements, the rise in forearm blood flow remained intact (forearm blood flow from 3.31 to 8.27 mL per 100 mL forearm volume per minute). However, inhibition of Ca2+-dependent potassium channels with tetraethylammonium chloride (0.1 mg per 100 mL forearm volume per minute) significantly attenuated vasodilation caused by CNP (forearm blood flow from 2.28 to 3.06 mL per 100 mL forearm volume per minute), which suggests that CNP opens vascular potassium channels. Vasodilation to all doses of CNP was significantly increased when activity of NEP was blocked with thiorphan (30 nmol/min), which suggests that NEP activity limits vasodilation of CNP. CNP is a dilator of human resistance vessels that mediates its effects through hyperpolarization of the vessel wall independent of the NO and prostaglandin system. Inhibition of local NEP activity increases CNP bioavailability. This may be of relevance to cardiovascular disease, given that vascular tone is well balanced between NO and an endothelium-derived hyperpolarizing factor, which suggests that in pathological situations, impaired NO activity can be compensated for by enhanced endothelium-derived hyperpolarizing factor release to maintain vascular homeostasis.
Key Words: natriuretic peptides • hyperpolarizing factor • endopeptidase • tetraethylammonium chloride • nitric oxide
This article has been cited by other articles:
 |
|
 |
|
  T. Kake, H. Kitamura, Y. Adachi, T. Yoshioka, T. Watanabe, H. Matsushita, T. Fujii, E. Kondo, T. Tachibe, Y. Kawase, et al. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice Am J Physiol Endocrinol Metab, December 1, 2009; 297(6): E1339 - E1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Mortensen, J. Gonzalez-Alonso, R. Damsgaard, B. Saltin, and Y. Hellsten Inhibition of nitric oxide and prostaglandins, but not endothelial-derived hyperpolarizing factors, reduces blood flow and aerobic energy turnover in the exercising human leg J. Physiol., June 1, 2007; 581(2): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Davidson, T. L. Kleinschmidt, C. L. Oltman, D. D. Lund, and M. A. Yorek Treatment of Streptozotocin-Induced Diabetic Rats With AVE7688, a Vasopeptidase Inhibitor: Effect on Vascular and Neural Disease Diabetes, February 1, 2007; 56(2): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S Garcha and A. D Hughes CNP, but not ANP or BNP, Relax Human Isolated Subcutaneous Resistance Arteries by an Action Involving Cyclic GMP and BKCa Channels Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 87 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 C. J. Kelsall, A. H. Chester, M. Amrani, and D. R.J. Singer C-Type Natriuretic Peptide Relaxes Human Coronary Artery Bypass Grafts Preconstricted by Endothelin-1 Ann. Thorac. Surg., October 1, 2005; 80(4): 1347 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Passauer, F. Pistrosch, E. Bussemaker, G. Lassig, K. Herbrig, and P. Gross Reduced Agonist-Induced Endothelium-Dependent Vasodilation in Uremia Is Attributable to an Impairment of Vascular Nitric Oxide J. Am. Soc. Nephrol., April 1, 2005; 16(4): 959 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schmitt, A. Qasem, C. McEniery, I. B. Wilkinson, V. Tatarinoff, K. Noble, J. Klemes, N. Payne, M. P. Frenneaux, J. Cockcroft, et al. Role of natriuretic peptides in regulation of conduit artery distensibility Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1167 - H1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Inokuchi, Y. Hirooka, H. Shimokawa, K. Sakai, T. Kishi, K. Ito, Y. Kimura, and A. Takeshita Role of Endothelium-Derived Hyperpolarizing Factor in Human Forearm Circulation Hypertension, November 1, 2003; 42(5): 919 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Chauhan, H. Nilsson, A. Ahluwalia, and A. J. Hobbs Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor PNAS, February 4, 2003; 100(3): 1426 - 1431. [Abstract] [Full Text] [PDF]
|
|